Drugs / Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)（GARDASIL®）
Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)（GARDASIL®）
also known as
GARDASIL
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05668572 Comparator | Dec 2020 → Jul 2022 | human papilloma virus infection | Beijing Health Guard Biotechnology, Inc | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)（GARDASIL） | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05668572 ↗ |
| Known as | GARDASIL | “quadrivalent HPV vaccine GARDASIL®” NCT05668572 ↗ |
| Modality | Vaccine | “quadrivalent HPV vaccine” NCT05668572 ↗ |